John Baldoni

Written By Yolandi Stanek
 

Ex-GSK, R&D Leader

 
 
 

John is a pharmaceutical industry veteran with more than 40 years of experience, including 29 years at GSK. An early champion of AI applications to accelerate drug discovery, John seeks out promising startups for advisory roles, which led him to BioSymetrics. Said John: "I am always looking for companies that can generate large amounts of relevant and consistent data to increase the chances of getting a drug to market and improve outcomes for patients faster. What is compelling about BioSymetrics is the coupling of their clinical and genomics insight directly with their biological assays. Their process is poised to improve translation of potential targets and reduce downstream failure in clinical trials."

John has participated in the research and development of many commercial medicines. He was previously SVP, Platform Technology and Science at GSK, SVP of in-silico drug discovery at GSK, and CTO of Valo Health. John conceptualized, founded, and is currently CEO of the ATOM consortium, a public-private partnership advancing drug discovery through a pre-competitive platform that integrates diverse data and high-performance computing.

Yolandi Stanek https://helloyo.com
Next

Yolanda Sanchez